Investigation of SP94 Peptide As a Specific Probe for Hepatocellular Carcinoma Imaging and Therapy

Overview

Journal Sci Rep

Specialty Science

Date 2016 Sep 22

PMID 27649935

Citations 12

Authors

Yanli Li

Yan Hu

Jie Xiao

Guobing Liu

Xiao Li

Yanzhao Zhao

Hui Tan

Hongcheng Shi

Dengfeng Cheng

Affiliations

Soon will be listed here.

Abstract

SP94 (SFSIIHTPILPL), a novel peptide, has shown specific binding to hepatocellular carcinoma (HCC) cells. We aimed to investigate the capability of SP94 as a targeting probe for HCC imaging and therapy following labeling with technetium-99m ((99m)Tc) and rhenium-188 ((188)Re). HYNIC-SP94 was prepared by solid phase synthesis and then labeled with (99m)Tc. Cell competitive binding, internalization assay, in vitro and in vivo stability, biodistribution and micro-single photon emission computed tomography /computed tomography (SPECT/CT) imaging studies were performed to investigate the capability of (99m)Tc tricine-EDDA/HYNIC-SP94 as a specific HCC imaging probe. Initial promising targeting results inspired evaluation of its therapeutic effect when labeled by (188)Re. HYNIC-SP94 was then labeled again with (188)Re to perform cell apoptosis, microSPECT/CT imaging evaluation and immunohistochemistry. Huh-7 cells exhibited typical apoptotic changes after (188)Re irradiation. According to (99m)Tc tricine-EDDA/HYNIC-SP94 microSPECT/CT imaging, tumor uptake was significantly decreased compared with that of pre-treatment with (188)Re-HYNIC-SP94. The immunohistochemistry also displayed obvious necrosis and apoptosis as well as inhibition of proliferation in the (188)Re-HYNIC-SP94 treatment group. The results supported that (99m)Tc tricine-EDDA/HYNIC-SP94 is able to target HCC cells and (188)Re-HYNIC- SP94 holds potential as a therapeutic agent for HCC, making (99m)Tc/(188)Re-HYNIC-SP94 a promising targeting probe for HCC imaging and therapy.

Citing Articles

Cancer Cell-Specific Fluorescent Prodrug Delivery Platforms.

Ma S, Kim J, Chen W, Li L, Lee J, Xue J Adv Sci (Weinh). 2023; 10(16):e2207768.

PMID: 37026629 PMC: 10238224. DOI: 10.1002/advs.202207768.

Genetically Engineered Hepatitis C Virus-like Particles (HCV-LPs) Tagged with SP94 Peptide to Acquire Selectivity to Liver Cancer Cells via Grp78.

Mofed D, Wahba M, Salem T Curr Issues Mol Biol. 2022; 44(8):3746-3756.

PMID: 36005152 PMC: 9406521. DOI: 10.3390/cimb44080256.

Curcumin- and resveratrol-co-loaded nanoparticles in synergistic treatment of hepatocellular carcinoma.

Zheng Y, Jia R, Li J, Tian X, Qian Y J Nanobiotechnology. 2022; 20(1):339.

PMID: 35858935 PMC: 9301856. DOI: 10.1186/s12951-022-01554-y.

Bifunctional chelators for radiorhenium: past, present and future outlook.

Melis D, Burgoyne A, Ooms M, Gasser G RSC Med Chem. 2022; 13(3):217-245.

PMID: 35434629 PMC: 8942221. DOI: 10.1039/d1md00364j.

Synthesis and Preclinical Evaluation of [Ga]SP94 for Micro-PET Imaging of GRP78 Expression in Hepatocellular Carcinoma.

Xu Y, Jiang J, Wang H, Yu W, Sun G ACS Med Chem Lett. 2021; 12(10):1553-1558.

PMID: 34676037 PMC: 8521616. DOI: 10.1021/acsmedchemlett.1c00350.

References

Decristoforo C, Faintuch-Linkowski B, Rey A, von Guggenberg E, Rupprich M, Hernandez-Gonzales I . [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Nucl Med Biol. 2006; 33(8):945-52. DOI: 10.1016/j.nucmedbio.2006.09.001. View

Toita R, Murata M, Abe K, Narahara S, Piao J, Kang J . A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells. Chem Commun (Camb). 2013; 49(67):7442-4. DOI: 10.1039/c3cc44508a. View

Li S, Liu J, Zhang H, Tian M, Wang J, Zheng X . Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med. 2001; 26(11):919-22. DOI: 10.1097/00003072-200111000-00006. View

Liu S . The role of coordination chemistry in the development of target-specific radiopharmaceuticals. Chem Soc Rev. 2004; 33(7):445-61. DOI: 10.1039/b309961j. View

Ji S, Zhou Y, Shao G, Liu S . Evaluation of K(HYNIC)(2) as a bifunctional chelator for (99m)Tc-labeling of small biomolecules. Bioconjug Chem. 2013; 24(4):701-11. PMC: 3667555. DOI: 10.1021/bc3006896. View

Erfani M, Ahrabi N, Shafiei M, Shirmardi S . A (99m) Tc-tricine-HYNIC-labeled peptide targeting the neurotensin receptor for single-photon imaging in malignant tumors. J Labelled Comp Radiopharm. 2014; 57(3):125-31. DOI: 10.1002/jlcr.3176. View

Ananias H, Yu Z, Dierckx R, van der Wiele C, Helfrich W, Wang F . (99m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm. 2011; 8(4):1165-73. DOI: 10.1021/mp200014h. View

Luo T, Tang I, Wu Y, Hsu K, Liu S, Kung H . Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment. Nucl Med Biol. 2009; 36(1):81-8. DOI: 10.1016/j.nucmedbio.2008.10.014. View

Yang Y, Ji S, Liu S . Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptides. Bioconjug Chem. 2014; 25(9):1720-9. PMC: 4166031. DOI: 10.1021/bc500309r. View

10.

Decristoforo C, Mather S . 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl Med Biol. 1999; 26(4):389-96. DOI: 10.1016/s0969-8051(98)00118-8. View

11.

Ashley C, Carnes E, Phillips G, Durfee P, Buley M, Lino C . Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano. 2011; 5(7):5729-45. PMC: 3144304. DOI: 10.1021/nn201397z. View

12.

Teodoro R, Faintuch B, Fernandez Nunez E, Queiroz R . Neurotensin(8-13) analogue: radiolabeling and biological evaluation using different chelators. Nucl Med Biol. 2011; 38(1):113-20. DOI: 10.1016/j.nucmedbio.2010.06.011. View

13.

Nguyen V, Law M, Dore G . Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009; 16(7):453-63. DOI: 10.1111/j.1365-2893.2009.01117.x. View

14.

Faintuch B, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith C . Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol. 2008; 35(4):401-11. DOI: 10.1016/j.nucmedbio.2008.02.005. View

15.

Zhang J . Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma. Autoimmun Rev. 2007; 6(3):143-8. PMC: 2740754. DOI: 10.1016/j.autrev.2006.09.009. View

16.

Garcia Garayoa E, Ruegg D, Blauenstein P, Zwimpfer M, Khan I, Maes V . Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues. Nucl Med Biol. 2007; 34(1):17-28. DOI: 10.1016/j.nucmedbio.2006.10.004. View

17.

Ocampo-Garcia B, Santos-Cuevas C, De Leon-Rodriguez L, Garcia-Becerra R, Ordaz-Rosado D, Luna-Guitierrez M . Design and biological evaluation of ⁹⁹mTc-N₂S₂-Tat(49-57)-c(RGDyK): a hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins. Nucl Med Biol. 2013; 40(4):481-7. DOI: 10.1016/j.nucmedbio.2013.01.003. View

18.

Yang J, Roberts L . Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010; 7(8):448-58. PMC: 3926946. DOI: 10.1038/nrgastro.2010.100. View

19.

Biechlin M, Bonmartin A, Gilly F, Fraysse M, du Moulinet dHardemare A . Radiolabeling of annexin A5 with (99m)Tc: comparison of HYNIC-Tc vs. iminothiolane-Tc-tricarbonyl conjugates. Nucl Med Biol. 2008; 35(6):679-87. DOI: 10.1016/j.nucmedbio.2008.05.009. View

20.

Reubi J . Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003; 24(4):389-427. DOI: 10.1210/er.2002-0007. View